Vascepa, approved in the U.S. to reduce triglycerides and cardiovascular events, helped Amarin generate $285.3M in net product revenue in 2023, a ~22% YoY decline from a year ago. More on Amarin ...

Generic drugmakers Hikma and Dr Reddy’s Laboratories have won a surprise victory in a US patent lawsuit that sets up early competition to cardiovascular drug Vascepa, Amarin’s only commercial ...

Amarin Corp PLC (AMRN) faces revenue challenges in the U.S. while expanding its global footprint and maintaining a strong cash position. AMRN's third-quarter 2024 earnings meet estimates while ...

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization ...

Amarin Corporation plc AMRN reported an adjusted loss of 5 cents per share for the third quarter of 2024, which was in line with the Zacks Consensus Estimate. The company had reported breakeven ...

Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s ...